Key result
Alagebrium chloride (ALT-711) therapy partially alleviated diabetes-induced diastolic dysfunction by decreasing isovolumetric relaxation time by 27% and myocardial performance index by 41%.
Why the study?
Does alagebrium chloride (ALT-711) improve cardiac dysfunction and SR Ca(2+) handling in streptozotocin-induced diabetic rats?
Does alagebrium chloride (ALT-711) improve cardiac dysfunction and SR Ca(2+) handling in streptozotocin-induced diabetic rats?
Effect estimate: 27% decrease
Absolute Event Rate: 37.3% vs 44.98%
p-value: p=<0.05
In a rat model of type 1 diabetes, treatment with the AGE cross-link breaker ALT-711 partially normalized SR calcium handling and improved diabetic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for ALT-711 in diabetic diastolic dysfunction; human trials needed before any clinical consideration.
Kranstuber et al. (2012) studied Diabetic cardiomyopathy (n=33). Alagebrium chloride (ALT-711) vs. Untreated diabetic rats was evaluated on Isovolumetric relaxation time (IVRT) (27% decrease, p=<0.05). Alagebrium chloride (ALT-711) therapy partially alleviated diabetes-induced diastolic dysfunction by decreasing isovolumetric relaxation time by 27% and myocardial performance index by 41%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: